Atacicept

S7A:4 Reduction of systemic lupus flares by atacicept in a randomised, placebo-controlled, phase iib study (address ii) and its extension study
DJ Wallace, DA Isenberg, A Kao, C Vazquez-Mateo, P Fleuranceau-Morel, P Chang, JT Merril

Lupus Science & Medicine Mar 2018, 5 (Suppl 1) A25-A26; DOI: 10.1136/lupus-2018-abstract.41
S7A:5 Sri response, attainment of low disease activity and safety in patients with systemic lupus treated with atacicept in a phase iib study (address ii)
JT Merril, E Morand, DJ Wallace, A Kao, C Vazquez-Mateo, P Chang, P Fleuranceau-Morel, DA Isenberg

Lupus Science & Medicine Mar 2018, 5 (Suppl 1) A26-A27; DOI: 10.1136/lupus-2018-abstract.42
PS7:133 Exposure-response modelling and exposure-safety modelling analyses in two phase ii studies of atacicept in sle
O Papasouliotis, O Yalkinoglu, C Vazquez Mateo, S Wax, A Kao, P Chang, P Fleuranceau-Morel, L Mahnke

Lupus Science & Medicine Mar 2018, 5 (Suppl 1) A101; DOI: 10.1136/lupus-2018-abstract.176

Main menu